Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.6
3.6
Journals
Diagnostics
Special Issues
Molecular Markers in Metabolic Diseases and Cancer
share announcement

Molecular Markers in Metabolic Diseases and Cancer

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Pathology and Molecular Diagnostics".

Deadline for manuscript submissions: 30 June 2024 | Viewed by 1192

Special Issue Editor

Dr. Roxana Popescu

E-Mail Website1 Website2
Guest Editor
Cell and Molecular Biology Department, “Victor Babeș” University of Medicine and Pharmacy of Timișoara, 300041 Timisoara, Romania
Interests: effects of xenobiotics, synthetic and biological compounds on 2D and 3D cellular systems; molecular markers in metabolic diseases and cancer

Special Issue Information

Dear Colleagues,

Cancer and metabolic diseases are a major public health problem. Despite the explosive development of medical–pharmaceutical technologies, morbidity and mortality related to these pathologies remain at alarming levels. Molecular markers include genes and genomic variations, differences in the expression of various types of RNA and proteins, post-translational modifications, as well as metabolite levels. These genomic, proteomic and metabolomic biomarkers can be advantageous tools with regard to clinical pathologies, particularly cancer and metabolic diseases. The elucidation of the molecular mechanisms related to the mentioned pathologies will enable the identification of potential markers for diagnosis, the early stratification of patients at risk, the assessment of prognosis and evolution, as well as therapeutic orientation.

This topic will foreground current and innovative research achievements in these areas. The submission of articles that attend to advances in medical research and aim to identify molecular markers with a role in the management of cancer and metabolic diseases is encouraged. Other related topics may also be addressed, such as advanced research technologies in cancer and metabolic diseases, interdisciplinary perspectives and computational models.

We welcome original research articles, communications, and review papers.

Dr. Roxana Popescu
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer
  • metabolic diseses
  • molecular markers
  • microRNAs
  • IHC

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

11 pages, 2568 KiB  
Article
Colorectal Cancer Risk Prediction Using the rs4939827 Polymorphism of the SMAD7 Gene in the Romanian Population
by Lucian-Flavius Herlo, Raluca Dumache, Ciprian Duta, Octavia Vita, Adriana Marina Mercioni, Lavinia Stelea, Roxana Sirli and Stela Iurciuc
Diagnostics 2024, 14(2), 220; https://doi.org/10.3390/diagnostics14020220 - 19 Jan 2024
Viewed by 889
Abstract
Colorectal cancer (CRC) is globally recognized as a prevalent malignancy known for its significant mortality rate. Recent years have witnessed a rising incidence trend in colorectal cancer, emphasizing the necessity for early diagnosis. Our study focused on examining the impact of the SMAD7 [...] Read more.
Colorectal cancer (CRC) is globally recognized as a prevalent malignancy known for its significant mortality rate. Recent years have witnessed a rising incidence trend in colorectal cancer, emphasizing the necessity for early diagnosis. Our study focused on examining the impact of the SMAD7 gene variant rs4939827 on the risk of colorectal cancer occurrence. The composition of our study group included 340 individuals, comprising 170 CRC diagnosed patients and 170 healthy controls. We performed genotyping of all biological samples using the TaqMan assay on the ABI 7500 Real-Time PCR System (Applied Biosystems, Waltham, MA, USA). This investigation focused on the rs4939827 gene variant, assessing its association with CRC risk and clinicopathological characteristics. Genotyping results for the SMAD7 gene variant rs4939827 revealed a 42.6% prevalence of the C allele in CRC patients (p = 0.245) and a 22.8% prevalence of the T allele in control subjects (p = 0.109). This study concluded that there was an elevated risk of CRC in the dominant model for CC/CT+TT, with a p-value of 0.113 and an odds ratio (OR) of 2.781, within a 95% confidence interval (CI) of 0.998 to 3.456. The findings of our research indicate a correlation between variants of the SMAD7 gene and the likelihood of developing colorectal cancer in our study population. Consequently, these results could be instrumental in facilitating early diagnosis of colorectal cancer utilizing information on single-nucleotide polymorphism (SNP) and genetic susceptibility to the disease. Full article
(This article belongs to the Special Issue Molecular Markers in Metabolic Diseases and Cancer)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop